Mae Hazell
3 Papers
Mae Hazell is an academic researcher. The author has contributed to research in topics: Vaccination & Dysbiosis. The author has co-authored 1 publications.
Chat about Author
Papers
Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
Rajeka Lazarus,Sarah Baos,Heike Cappel-Porter,Andrew Carson-Stevens,Madeleine Clout,Lucy Culliford,Stevan R Emmett,Jonathan Garstang,Lukuman Gbadamoshi,Bassam Hallis,Rosie A Harris,David Hutton,Nick Jacobsen,Katherine Joyce,Rachel Kaminski,Vincenzo Libri,Alex Middleditch,Liz McCullagh,Ed Moran,Adrian Phillipson,Elizabeth Price,John M Ryan,Russell C J Thirard,Rachel Todd,Matthew D. Snape,David Tucker,Rachel Williams,Jonathan S. Nguyen-Van-Tam,Adam Finn,Chris A Rogers,Kirsty Adams,Seema Alaee,Parvinder K. Aley,Emma Allum,Sally Anthony,Kate Ashton,Tanya Awal,Liz Barnett,Alison Barratt,Charlotte Barron,Holly Baum,Chloe Beard,Lorna Bennett,Samuel Bird,Sarah Bishop,Jess Bisset,Pritesh Bodalia,Jane Bowles,Catherine Bowyer,Kirstie Bradburn,Jonathan J.H. Bray,Catherine Bressington,Matthew Brimfield,Lauren Broad,Pauline Brown,Ruth Brydon-Hill,Sharon Burge,David Carmichael,Gurjit Chohan,Tonia Clark,Adrianne Close,Tom Coleman,Claire Cowley,Charlotte Cranfield,Eleanor Cross,Alyssa D'Agostino,Silvia D'Arcangelo,Ashley Otter,Kate Davies,Catrin Davies,Ru Davies,Louisa Davies,Kimberley Driver,Charlotte Eglinton,Charlotte Ekblad,Emma Eldridge,Teriann Evans,Mim Evans,Isabel Evans,Yama F Mujadidi,Amanda Farrow,Beverley Faulkner,Sally Feltham,Susan Figueirido,Jamie Ford,David Foxwell,Sharon Frayling,Sophie Gardiner,Karen E. Gooch,Jayne Goodwin,Alice Halliday,Shama Hamal,Sarah Harrhy,Andrew Harris,Lesley Haxton,Matthew Haynes,Mae Hazell,Tracey Hembrough,Jacqueline Hewson,Bethany Hicks,T. Twistington Higgins,Michelle Hill,Alex Hills,Zoe Hilton,Benjamin Hitchings,Cheryl Hua,Hina Iftikhar,Attya Iqbal,Laura Jones,Nicola Jones,Johanna K Kellett Wright,Sarah Kidd,Alison Kirby,Lucy Knibbs,Jenny Lamb,Helen Langton,Rwth Leach,Phoebe Lewis-Clarke,Amy Lloyd,Kirsty Maclean,Nicola Manning,Anthony Marriott,Isobel Joy McFadzean,Maeve McLaughlin,Alison McQueen,Bianca Mills,Gurudutt Naik,Lisa Nicholls,Chris Norman,Keren Northcott,Kerry Nyland,Catherine Oliver,Elizabeth Oliver,Jennifer Oliver,Diana Owen,Jemma Paterson,Lauren Pearce,Suzannah Pegler,Zoe Price,William B. Pynsent,Lidia Ramos,Tommy Rampling,David Rea,Karen Regan,Tawassal Riaz,Marivic Ricamara,Danielle Rice,Melody Rich,Marianne Roots,Kathryn Ann Ryan,Yukari Sakagami,Ahmed Salem,Jade Salter-Hewitt,Michelle Samuels,Silvia Santoloce,Siwan Seaman,Michael Seneviratne,Sara Shankland,Louise Silva,Katie Smart,Rachel M. Smith,Joyce Smith,Rebecca Stringer,Helen Talbot,Teresa Tarling,Sarah Louise Taylor,Amy Hughes Thomas,Grace Tilzey,Gina Townley,Lisa Trembath,Kate Turkentine,Kelly Turner,Jenny Tyler,Jacinta Ugoji,Katharine Wale,Terrie Walker-Smith,Maggie Walton,Barbara Warnes,Sarah Whittley,Jennie Williams,Gail M. Williams,Kevin Williamson,Yee Ting Nicole Yim,Nicola Youlden +183 more
TL;DR: In this article, the safety of concomitant vaccination with COVID-19 and influenza vaccines was evaluated in a randomized, controlled, phase 4 trial, where participants were randomly assigned to receive either an age-appropriate influenza vaccine or placebo alongside their second dose of COVID19 vaccine.
93
High resolution 16S rRNA gene Next Generation Sequencing study of brain areas associated with Alzheimer’s and Parkinson’s disease
David C. Emery,Maria Davies,Tanya L Cerajewska,Jelena Taylor,Mae Hazell,Alex Paterson,Shelley J. Allen-Birt,Nicola X West +7 more
TL;DR: In this paper , the authors used 16S rRNA PCR-based Next Generation Sequencing (16SNGS) to characterize bacterial composition in brain areas associated with the early, intermediate and late stages of Alzheimer's and Parkinson's disease.
11
Adalimumab vs placebo as add-on to Standard Therapy for autoimmune Uveitis: Tolerability, Effectiveness and cost-effectiveness-a protocol for a randomised controlled trial (ASTUTE trial).
Mae Hazell,Barnaby C Reeves,Chris A Rogers,Katie Pike,Lucy Culliford,Sarah Baos,Mandy P Y Lui,Nicholas A V Beare,Carlos Pavesio,Alastair K Denniston,Sarah Wordsworth,P. Keane,A. Folkard,T. Peto,Srilakshmi M Sharma,Andrew Dick +15 more
TL;DR: The ASTUTE trial will recruit patients with ANIU who do and do not meet funding criteria and will evaluate the effectiveness and cost-effectiveness of adalimumab versus placebo as an add-on therapy to standard care.